Three-year remission rate up to 94%! Johnson & Johnson (JNJ.US) Tremfya Crohn's disease study long-term data achieve positive results.

Zhito Finance APP has learned that long-term data from two Phase 3 clinical trials of Johnson & Johnson (JNJ.US) show that adult Crohn's disease patients treated with Tremfya (guselkumab) achieved clinical remission rates of up to 94% within three years.